Monatepil
 | |
| Names | |
|---|---|
| Preferred IUPAC name N-(6,11-Dihydrodibenzo[b,e]thiepin-11-yl)-4-[4-(4-fluorophenyl)piperazin-1-yl]butanamide | |
| Identifiers | |
CAS Number |
|
3D model (JSmol) |
|
| ChemSpider |
|
| KEGG |
|
PubChem CID |
|
| UNII |
|
CompTox Dashboard (EPA) |
|
InChI
| |
| |
| Properties | |
Chemical formula | C28H30FN3OS |
| Molar mass | 475.63 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).  N verify (what is  Y N ?) Infobox references | |
Chemical compound
Monatepil is a calcium channel blocker and α1-adrenergic receptor antagonist used as an antihypertensive.[1]
References
- ^ Sugimoto T, Hosoki K, Karasawa T (July 1995). "Relative contribution of alpha 1-adrenoceptor blocking activity to the hypotensive effect of the novel calcium antagonist monatepil". Journal of Cardiovascular Pharmacology. 26 (1): 55–60. doi:10.1097/00005344-199507000-00009. PMID 7564365. S2CID 1548014.
- v
- t
- e
(antagonize α-adrenergic
vasoconstriction)
| Central |
| ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Peripheral |
|
| Serotonin receptor antagonists | |
|---|---|
| Endothelin receptor antagonists (for PHTooltip Pulmonary hypertension) |
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
 | This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
